CAS 30299-08-2: clinofibrate
Formula:C28H36O6
InChI:InChI=1S/C28H36O6/c1-5-26(3,24(29)30)33-22-14-10-20(11-15-22)28(18-8-7-9-19-28)21-12-16-23(17-13-21)34-27(4,6-2)25(31)32/h10-17H,5-9,18-19H2,1-4H3,(H,29,30)(H,31,32)
InChI key:InChIKey=BMOVQUBVGICXQN-UHFFFAOYSA-N
SMILES:O(C(C(O)=O)(CC)C)C1=CC=C(C2(CCCCC2)C3=CC=C(OC(C(O)=O)(CC)C)C=C3)C=C1
Synonyms:- 1,1-Bis[4'-(1''-carboxy-1''-methylpropoxy)phenyl]cyclohexane
- 2,2'-(Cyclohexylidenebis(4,1-Phenyleneoxy))Bis(2-Methyl)-Butanoic Acid
- 2,2'-[Cyclohexane-1,1-Diylbis(Benzene-4,1-Diyloxy)]Bis(2-Methylbutanoic Acid)
- 2,2’-(4,4’-Cyclohexylidenediphenoxy)-2,2’-Dimethyldibutyricacid
- 2,2’-Cyclohexane-1,1-Diylbis(P-Phenyleneoxy)Bis(2-Methylbutyricacid)
- 2,2’-Cyclohexane-1,1-Diylbis(P-Phenyleneoxy)Bis-(2-Methyl-Butyricaci
- 2,2′-[Cyclohexylidenebis(4,1-phenyleneoxy)]bis[2-methylbutanoic acid]
- Butanoic acid, 2,2′-[cyclohexylidenebis(4,1-phenyleneoxy)]bis[2-methyl-
- Clinofibrate(Forr&Donly)
- Lipoclin
- S 8527
- See more synonyms
Sort by
Found 8 products.
Clinofibrate
CAS:Clinofibrate lowers lipids, blocks HMGCR (IC50: 0.47 mM), and controls cholesterol/triacylglycerides.Formula:C28H36O6Purity:99.84%Color and Shape:White Crystalline PowderMolecular weight:468.58Clinofibrate
CAS:Formula:C28H36O6Purity:>98.0%(HPLC)Color and Shape:White to Almost white powder to crystalMolecular weight:468.59Clinofibrate
CAS:Controlled ProductApplications An antilipemic, used as an anti-atherosclerosis agent References Cercos-Del-Pozo, R., et al.: J. Pharm. Pharmacol., 48, 240 (1996), Tomiyama, N., et al.: Clin. Exper. Pharmacol. Physiol., 34, 876 (2007),Formula:C28H36O6Color and Shape:NeatMolecular weight:468.582,2?-((Cyclohexane-1,1-Diylbis(4,1-Phenylene))Bis(Oxy))Bis(2-Methylbutanoic Acid)
CAS:2,2?-((Cyclohexane-1,1-Diylbis(4,1-Phenylene))Bis(Oxy))Bis(2-Methylbutanoic Acid)Purity:98%Molecular weight:468.58g/molClinofibrate
CAS:Clinofibrate is a hypolipidemic agent that is used to lower serum cholesterol levels. It is a prodrug that is converted to its active form, clofibrate, in the liver. Clinofibrate inhibits hydroxylation of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) by inhibiting the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, which is involved in the synthesis of cholesterol. Clinofibrate also has been shown to reduce atherosclerotic plaque formation in animal models and has been shown to have pharmacokinetic properties similar to those of other hypolipidemic agents.Formula:C28H36O6Purity:Min. 95%Molecular weight:468.58 g/molRef: 3D-FC20487
Discontinued productButanoic acid, 2,2'-[cyclohexylidenebis(4,1-phenyleneoxy)]bis[2-methyl-
CAS:Formula:C28H36O6Purity:98%Color and Shape:SolidMolecular weight:468.5818
![Butanoic acid, 2,2'-[cyclohexylidenebis(4,1-phenyleneoxy)]bis[2-methyl-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA002ZJP.jpg&w=3840&q=75)
